Liraglutide treatment for the prevention of glucose tolerance deterioration in women with prior gestational diabetes mellitus: A 52‐week randomized controlled clinical trial

• DOI: 10.1111/dom.15306
• Publication Date: 2023-10-17T08:37:20Z
• Authors: Signe Foghsgaard; Louise Vedtofte; Emilie S. Andersen; Emilie Bahne; Camilla Andreasen; Anne L. Sørensen; Julie L. Forman; Elisabeth R. Math...; Jens A. Svare; Tine D. Clausen; Peter Damm; Jens J. Holst; Filip K. Knop; Tina Vilsbøll
• Keywords: GLP-1 analogue; liraglutide; clinical trial; incretin therapy; GLP-1; 3. Good health

We investigated the effect of 52-week treatment with liraglutide, a glucagon-like peptide 1 receptor agonist, on glucose tolerance and incretin in women previous gestational diabetes mellitus (pGDM).Women overweight/obesity pGDM were randomized to once daily subcutaneous liraglutide 1.8 mg or placebo for 52 weeks. Participants underwent oral test (OGTT) isoglycaemic intravenous infusion at baseline weeks, an additional OGTT after drug wash-out.In total, 104 [age: mean ± SD, 38 5 years; fasting plasma (FPG): 5.5 0.4 mmol/L; glycated haemoglobin (HbA1c): 33 4 mmol/mol, bodyweight: 88.2 14.8 kg, body mass index: 31.1 4.3 kg/m2 ] assigned (n = 49) 55). Estimated difference (ETD) area under curve during was -173 (95% confidence interval -250 -97) mmol/L × min, p < .0001, but wash-out disappeared [ETD 58 (-30 146) .536]. Liraglutide reduced FPG -0.2 (-0.4 -0.1) mmol/L, .018], HbA1c [-2.2 (-3.5 -0.8) .018] bodyweight [-3.9 (-6.2 -1.6) .012]. No change observed. The number prediabetes from 64% 10% vs. 50% [adjusted odds ratio 0.10 (0.03-0.32), .002].Treatment weeks improved tolerance, FPG, pGDM. Progression while markedly reduced, 1-week wash-out, lost.